Loading...
Loading...
RGLS| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 15.2M |
| Operating I/L | -15.2M |
| Other Income/Expense | 1.1M |
| Interest Income | 1.2M |
| Pretax | -14.1M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -14.1M |
Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat various diseases. The company's product candidates include RG-012, an anti-miR targeting miR-21 in Phase II clinical trial for Alport syndrome, and RGLS8429, an anti-miR targeting miR-17 in Phase 1b clinical study for autosomal dominant polycystic kidney disease. Additionally, Regulus is developing a pipeline of preclinical drug products for target organ-selective delivery strategies.
